AzTrials
AzTrials

Spinal Cord InjuryPhase 1/2NCT02317640

TRT in Combination With Electrical Stimulation and Standing: Effect on Muscle and Bone in Spinal Cord Injured Males

A Phase 1/2 study testing Testosterone Gel applied by a pump, Stand Training and Electrical Stimulation in people with Spinal Cord Injury, run by Kessler Foundation at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of this study is to understand what happens to muscle and bone in spinal cord injured males after four months of training using stand training, with body weight support (BWS), with testosterone replacement therapy (TRT), and electrical stimulation (ES). Read more about this study

Who is it for?
Ages 18 to 58 years, men only
Conditions the study is for
Spinal Cord Injury
What is being tested?
Testosterone Gel applied by a pump, Stand Training and Electrical Stimulation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
56 participants
Where
1 siteUnited States
Study dates
15 Mar 2017to Oct 2022
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 58 years
  • Men only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Must be a male between 18 and 58 years old;
  • Must have a spinal cord injury at a neurological level of injury between the C6-T10 level and an impairment grade A, B, or C, according to the American Spinal Injury Association (ASIA) Impairment Scale. If a person with quadriplegia their motor level will be used instead of neurological level. As a quadraplegic the motor level must be between C6-T10;
  • Must be able to tolerate electrical stimulation and must show visible muscle contraction to an electrical stimulus;
  • Must be wheelchair reliant for more than 75% of the time;
  • Must have low testosterone levels (300-325 ng/dL) as determined by a blood test done at the baseline study visit.

Who cannot join

  • Taking spasticity medication (i.e., baclofen). It may be possible that participant can be weaned off of the spasticity medication prior to starting entry into the study. This would be under the guidance of the study physician.
  • Less than 6 months or greater than 10 years post injury;
  • A score >3 on the Modified Ashworth Scale as determined by study staff;
  • Bone density measurement for the knee is at or below .5755 gm/cm2 as recorded by study staff;
  • Weigh more than 225 lbs;
  • Taller than 6 feet 3 inches;
Show all 37Show fewer
  • Presence of a cardiovascular disease;
  • Presence of pulmonary disease;
  • Presence of recent lower limb fractures;
  • Presence of severe contractures;
  • Presence of lower extremity deep vein thrombosis (within the last three months) or other major medical illness;
  • Taking medications known to influence bone metabolism as determined by study staff review of medications;
  • A major gastrointestinal problem such as swallowing or gastrointestinal reflux disease;
  • Heart rate or rhythm problems;
  • A pacemaker;
  • Had spinal fusion, must have approval from the referring physician to receive ES - assisted standing prior to acceptance into the study;
  • As determined by study staff and review of medications, taking medication known to affect my level of testosterone;
  • A PSA greater than or equal to 4.0 ng/ml as determined by blood tests during screening visit;
  • An elevated PSA or asymmetry or hardening of prostate as determined by blood tests and digital rectal examination at screening visit.
  • Any known heart or blood vessel problems (cardiovascular disease)
  • An acute illness of any cause;
  • History of anabolic steroid use as determined by study staff review of participant's medical records;
  • Have a hematocrit greater than or equal to 55 as measured by the study team.
  • Have an abnormal liver function test from the hepatic panel (greater than 2.5 times the normal value) as measured by the study team;
  • Have an abnormal digital rectal exam (DRE) at baseline suggestive of malignancy;
  • Currently abuse alcohol or drugs;
  • Have a significant psychological disorder;
  • Have a history of or a current malignancy;
  • Wish to contribute to the conception of a child.
  • If any of the following occurs in the experimental group following initiation of testosterone replacement therapy participation will be terminated.
  • Hematocrit greater than or equal to 55;
  • Abnormal liver function test from the hepatic panel (greater than 2.5 times the normal value);
  • Worsening of any sleep disorder, as determined by the Investigators;
  • A PSA greater than or equal to 4.0 ng/ml;
  • Worsening of mood disorders; i.e. anger and depression as determined by the investigators;
  • Planning to contribute to the conception of a child during the study period.
  • Have participated in an electrical stimulation or TRT study in the previous 3 months.

Trial locations and contacts

1 site in 1 country.

United States1 site, 1 recruiting
  • Kessler Foundation

    West Orange, New Jersey, 07052

    Gail F Forrest, Ph.D, 973-324-3518, gforrest@kesslerfoundation.org

    Recruiting

Other trials in United States

About this study

Official title: Testosterone Replacement Therapy in Combination With Electrical Stimulation and Standing: Effect on Muscle and Bone in Spinal Cord Injured Males.

The aim of this study is to understand what happens to muscle and bone in spinal cord injured males after four months of training using stand training, with body weight support (BWS), with testosterone replacement therapy (TRT), and electrical stimulation (ES). Specifically, researchers will investigate nerve, muscle, and bone changes in the lower limbs in response to stand training and ES when combined with TRT compared to i) standing alone with TRT; ii) stand training alone with placebo; iii) stand training alone and ES with placebo.

Read the detailed description

Primary Aim:

To assess the effects of our novel tri combination Activity-Dependent Rehabilitation model approach on muscle volume of the lower limbs.

Secondary Aims:

  1. To better define the mechanisms that contribute to changes in muscle.

Preliminary data from animal studies have shown increased expression of Activin receptor IIB and increased nuclear localization of Smad2 and Smad3 after SCI and that these adverse changes are reversed by androgens. Additional studies will examine mRNA levels for myostatin, its receptor and its inhibitors (e.g., follistatins) and determine nuclear levels of Smad2 and Smad3. We will also measure resting energy expenditure to confirm that changes in muscles mass correspond to anticipated metabolic effects.

ii) To evaluate the changes in bone and bone structure with Stand Training with TRT and ES.

Individuals with SCI not only lose motor and/or sensory function, they experience dramatic muscle and bone loss. Locomotor training, an activity-based intervention that engages the neuromuscular system below the level of lesion for standing and walking enhances EMG activity and has shown modest improvements in muscle without any attenuation in bone density [172-177]. Dynamic stand training, an important component of locomotor training, provides sensory feedback related to standing and bilateral weight bearing, resulting in bilateral muscle activation via central pathways through the spinal cord [161,178-181]. Thus, the stand retraining component provides a physiologically relevant multi-muscle activation through central pathways, dynamic gravity opposed loading of the legs and additional task specific activation of the muscles [161,162,179]. Functional electrical stimulation is a method of exercise that has been employed in the SCI population and has demonstrated success in improving muscle, with less conclusive evidence for its effect on bone albeit there has been speculation that although slowing or preventing bone loss may be feasible after SCI, reversing such bone loss (i.e. restoring bone) is not possible, although the evidence is primarily from applying FES to single muscles [151,171]. TRT has been shown to offer a logical, efficacious, and cost-effective intervention to, in part, counteract these untoward body composition, metabolic, and functional sequelae of relative hypogonadism in those with chronic SCI [37]. In addition, testosterone alone has been shown to increase muscle mass, muscle strength, and bone in androgen-deficient men and older men with low testosterone levels [182,183]. The model of compressive loads generated during the combination of stand retraining and multi muscle ES will be multi-directional and will increase muscle strength and the forces applied to the hip, femur and tibia bones. We anticipate that the model of standing plus TRT will increase muscle mass and strength more than standing alone. The combination of multi muscle TRT+ES while stand training will further increase muscle strength compared to either arm alone, resulting in an increased synergistic response of benefit which will surpass the threshold needed to significantly increase bone restoration [102,184,185].This novel tri-combination synergistic approach of TRT, ES, and Stand Training is being hypothesized to increase muscle mass and strength to a greater extent than that of each alone or than that of only two of these interventions. Measurements of muscle torques will be obtained to demonstrate a quantifiable relationship between muscle strength and bone mass.

Being tested
Testosterone Gel applied by a pump, Stand Training, Electrical Stimulation
Keywords
Testosterone, Electrical Stimulation, Stand Training
Medical subject headings
Spinal Cord Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Testosterone Gel applied by a pumpDrug

    Also called Androgel 1.62%

    After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.

  • Stand TrainingOther

    Also called Locomotor Training

    Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.

  • Electrical StimulationDevice

    Also called ES

    Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.

Study groups in NCT02317640
Study groupRoleWhat they receive
Stand Training AloneActive comparatorStanding training will be prescribed 3 days/week (1.5 hours/sessions) for 60 sessions. All individuals randomized to stand training will train with BWST with manual assistance and will undergo a stand evaluation. During the evaluation the participants will be placed on the treadmill in an upright position and suspended in a harness by an overhead cable (i.e. BWST). A trainer will be positioned to assist the participant while standing and to provide manual assistance if needed. The amount of BWS and level of assistance given for each body segment will be recorded. The BWS level at which the participant can independently support good standing posture will also be recorded. Standing time while on treadmill and overground will be recorded daily as part of the training sessions.
Receives: Other: Stand Training
ST with placebo or testosteroneExperimentalStand Training as described above with Placebo or testosterone Gel applied by a pump. After a baseline testing period, TRT will begin in the treatment groups by application of a daily dose of 40.5 mg of testosterone or placebo gel. The gel is to be applied to the upper arms and shoulders and is absorbed and eliminated over the course of a day. To ensure proper dosing serum T concentration will be assessed at screening, baseline, 2 weeks, 1 month and 3 month time points. As such, follow-up with the participant will be necessary to determine the correct replacement dose of TRT, and adjustment of dose if needed, (i.e. 40.5 mg up to 81 mg of gel). If serum T levels are not within normal range at the 2 week time point, the dose will be increased in increments of 20.25 mg up to 81 mg.
Receives: Drug: Testosterone Gel applied by a pump; Other: Stand Training
ST with Placebo or Testosterone and ESExperimentalStand Training described above with Placebo or testosterone gel applied by a pump. Electrical stimulation will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points (both legs) on the following muscles: gluteus maximus (GL), rectus femoris (RF), biceps femoris (BF), gastrocnemei (GC), and anterior tibialis (TA) of both legs. Two electrodes will be used for each muscle. One "RT300 portable stimulator" (Restorative Therapies, Inc., Baltimore, MD) will be used to induce the electrical stimulation with 10 sets of electrodes for stimulation.
Receives: Drug: Testosterone Gel applied by a pump; Other: Stand Training; Device: Electrical Stimulation
ST with ESExperimentalStand Training as described above in Stand Training alone and Electrical Stimulation as described above in ST with Placebo or Testosterone and ES.
Receives: Other: Stand Training; Device: Electrical Stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Muscle Volume (percent change in muscle volume for the bilateral thigh)

    Muscle volume will be measured in the thigh. The percent change in muscle volume for the bilateral thigh will be compared to before the intervention to after the intervention.

    Measured: 38 weeks

Secondary outcomes (2)
  1. Change in Muscle (increase in muscle torque)

    To assess whether the tri-combination of stand training with TRT and ES will lead to increased muscle strength and contractile elements of muscle as shown by an increase in muscle torque.

    Measured: 38 weeks

  2. Change in Bone (BMD of the proximal tibia and distal femur)

    To evaluate change in bone and bone structure with stand training with TRT and ES will include BMD of the proximal tibia and distal femur; these are the most common sites for fracture and may also respond faster to intervention. Other secondary outcome measures will be BMD at the hip, cortical and trabecular bone with 3-D volumetric measurements, and bone markers for formation and resorption.

    Measured: 38 Weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Dec 2014 (estimated)
  2. Study start15 Mar 2017
  3. Primary completionOct 2022 (estimated)
  4. Study completionOct 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
56 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02317640
Sponsor's protocol ID
DOD SC130243
Status last verified
Aug 2017
First submitted
6 Dec 2014
Last updated
22 Aug 2017
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Testosterone Gel applied by a pump, Stand Training and Electrical Stimulation in people with Spinal Cord Injury, run by Kessler Foundation at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 37 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Gail F Forrest, PhD (973-324-3518 ext. 3518, gforrest@kesslerfoundation.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Muscle Volume (percent change in muscle volume for the bilateral thigh) (time frame: 38 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2017.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in